Medesis Pharma SA
PAR:ALMDP
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| FR |
|
Medesis Pharma SA
PAR:ALMDP
|
1.8m EUR |
Loading...
|
|
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
198.2B USD |
Loading...
|
|
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR |
Loading...
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD |
Loading...
|
|
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
104.1B ZAR |
Loading...
|
|
| US |
|
Schlumberger NV
NYSE:SLB
|
73.9B USD |
Loading...
|
|
| US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
56.8B USD |
Loading...
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
34.6B CHF |
Loading...
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
37.1B USD |
Loading...
|
|
| US |
|
Symbotic Inc
NASDAQ:SYM
|
32B USD |
Loading...
|
|
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.8B ZAR |
Loading...
|
Market Distribution
| Min | -147 400% |
| 30th Percentile | -2.2% |
| Median | 2.6% |
| 70th Percentile | 7.1% |
| Max | 14 243.8% |
Other Profitability Ratios
Medesis Pharma SA
Glance View
Medesis Pharma SA operates as a clinical development stage biopharmaceutical company. The company is headquartered in Baillargues, Occitanie. The company went IPO on 2021-02-12. The firm is engaged through its drug delivery technology Aonys in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address unmet medical needs. Its technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue). The Company’s two drug candidates for treating people contaminated following a civil or military nuclear accident are Plutonium decorporation and Cesium decorporation.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
Over the last 0 months, Medesis Pharma SA’s Net Margin has decreased from -3 620.5% to -3 620.5%. During this period, it reached a low of -3 620.5% on Jan 1, 2022 and a high of -3 620.5% on Jan 1, 2022.
